Министерство здравоохранения Российской Федерации; Российское респираторное общество. Хроническая обструктивная болезнь легких. Клинические рекомендации. 2018. Режим доступа: https://legalacts.ru/doc/klinicheskie-rekomendatsii-khronicheskaja-obstruktivnaja-bolezn-legkikh-utv-minzdravom-rossii/https://legalacts.ru/doc/klinicheskie-rekomendatsii-khronicheskaja-obstruktivnaja-bolezn-legkikh-utv-minzdravom-rossii/
Министерство здравоохранения Российской Федерации; Российское респираторное общество. Хроническая обструктивная болезнь легких. Клинические рекомендации. 2018. Режим доступа: https://legalacts.ru/doc/klinicheskie-rekomendatsii-khronicheskaja-obstruktivnaja-bolezn-legkikh-utv-minzdravom-rossii/https://legalacts.ru/doc/klinicheskie-rekomendatsii-khronicheskaja-obstruktivnaja-bolezn-legkikh-utvminzdravom-rossii/
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2017. Available at: https://goldcopd.org/gold-2017-global-strategy-diagnosismanagement-prevention-copd/https://goldcopd.org/gold-2017-global-strategy-diagnosismanagement-prevention-copd/
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2017. Available at: https://goldcopd.org/gold-2017-global-strategy-diagnosismanagement-prevention-copd/https://goldcopd.org/gold-2017-global-strategy-diagnosismanagement-prevention-copd/
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2019. Available at: www.goldcopd.com.www.goldcopd.com
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2019. Available at: www.goldcopd.com.www.goldcopd.com
Åberg J., Hasselgren M., Montgomery S., Lisspers K., Ställberg B., Janson C., Sundh J. Sex-related differences in management of Swedish patients with a clinical diagnosis of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;(14):961-969. doi: 10.2147/COPD.S193311..
DOI: 10.2147/COPD.S193311
Duarte-de-Araújo A., Teixeira P., Hespanhol V., Correia-de-Sousa J. Characterisation of morbidity in a COPD hospital cohor. Pulmonology. 2019;25(4):200-207. doi: 10.1016/j.pulmoe.2019.02.010..
DOI: 10.1016/j.pulmoe.2019.02.010
Салахова И.Н., Вафина А.Р., Визель И.Ю., Визель А.А., Ильинский В.И., Шакирова Г.Р., Кудрявцева Э.З. Перераспределение больных хронической обструктивной болезнью легких в соответствии с изменениями классификации глобальной инициативы GOLD. Фарматека. 2018;(8):66- 71. doi: 10.18565/pharmateca.2018.8.66-71..
DOI: 10.18565/pharmateca.2018.8.66-71
Brożek G.M., Nowak M., Zejda J.E., Jankowski M., Lawson J., Pierzchała W. Consequences of changig the GOLD reports (2007-2011-2017) on the treatment regimen of patients with COPD. COPD. 2019;16(1):1-7. doi: 10.1080/15412555.2019.1615872..
DOI: 10.1080/15412555.2019.1615872
Avdeev S., Aisanov Z., Arkhipov V., Belevskiy A., Leshchenko I., Ovcharenko S., Shmelev E., Miravitles M. Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms. International Journal of Chronic Obstructive Pulmonary Disease 2019;14:1267– 1280. doi: 10.2147/COPD.S207775..
DOI: 10.2147/COPD.S207775
Grove A., Lipworth B.J., Reid P., Smith R.P., Ramage L., Ingram C.G., Jenkins R.J., Winter J.H., Dhillon D.P. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax. 1996;51(7):689-693. doi: 10.1136/thx.51.7.689..
DOI: 10.1136/thx.51.7.689
Vaz Fragoso C.A., Gill T.M., Leo-Summers L.S., Van Ness P.H. Re-evaluation of combination therapy in chronic obstructive pulmonary disease (COPD). Respir Med. 2019;(151):27-34. doi: 10.1016/j.rmed.2019.03.020..
DOI: 10.1016/j.rmed.2019.03.020
Rabe K.F., Ukena D., Magnussen H. Longacting beta(2)-adrenoceptor agonists for asthma and COPD. Med Klin (Munich). 1997;92(5):44-49. doi: 10.1007/BF03041980..
DOI: 10.1007/BF03041980
Cazzola M., Santus P., Di Marco F., Carlucci P., Mondoni M., Matera M.G., Centanni S. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm Pharmacol Ther. 2004;17(3):121-125. doi: 10.1016/j.pupt.2004.01.001..
DOI: 10.1016/j.pupt.2004.01.001
Welte T. Optimising treatment for COPD – new strategies for combination therapy. Int. J. Clin. Pract. 2009;63(8):1136-1149. doi: 10.1111/j.1742-1241.2009.02139.x..
DOI: 10.1111/j.1742-1241.2009.02139.x
Callejas González F.J., Genovés Crespo M., Cruz Ruiz J., Godoy Mayoral R., Agustín Martínez F.J., Martínez García A.J., Tárraga López P.J. UPLIFT study – understanding potential long-term impacts on function with tiotropium - and subanalyses. Bibliographic resume of the obtained results. Expert Rev Respir Med. 2016;10(9):1023- 1033. doi: 10.1080/17476348.2016.1188693..
DOI: 10.1080/17476348.2016.1188693
Spila-Alegiani S., Trotta F., Da Cas R., Rossi M., Venegoni M., Traversa G. Comparative effectiveness of two tiotropium formulations: a retrospective cohort study. COPD. 2018;15(5):418-423. doi: 10.1080/15412555.2018.1554032..
DOI: 10.1080/15412555.2018.1554032
Brand P., Hederer B., Austen G., Dewberry H., Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFAMDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3(4):763- 770. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650591/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650591/
Brand P., Hederer B., Austen G., Dewberry H., Meyer T. Higher lung deposition with Respimat Soft Mist inhaler than HFAMDI in COPD patients with poor technique. Int J Chron Obstruct Pulmon Dis. 2008;3(4):763- 770. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650591/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650591/
Deeks E.D. Olodaterol: a review of its use in chronic obstructive pulmonary disease. Drugs. 2015;75(6):665-673. doi: 10.1007/s40265- 015-0371-4..
DOI: 10.1007/s40265- 015-0371-4
Blair H.A. Tiotropium/Olodaterol: A review in COPD. Drugs. 2019;79(9):997-1008 doi: 10.1007/s40265-019-01133-w..
DOI: 10.1007/s40265-019-01133-w
Maltais F., Hamilton A., Voß F., Maleki-Yazdi M.R. Dose determination for a fixed-dose drug combination: A phase II randomized controlled trial for tiotropium/olodaterol versus tiotropium in patients with COPD. Adv Ther. 2019;36(4):962-968. doi: 10.6084/m9.figshare.7713635..
DOI: 10.6084/m9.figshare.7713635
Russell R.E.K. What Does the TOVITO Programme Tell Us about How We Can Manage COPD? Turk Thorac J. 2018;19(4):216- 219. doi: 10.5152/TurkThoracJ.2018.182609..
DOI: 10.5152/TurkThoracJ.2018.182609
Corsico A.G., Braido F., Contoli M., Di Marco F., Rogliani P., Scognamillo C., Olivi I., Santus P., Scichilone N., Lazzaro C. Healthcare costs of the SATisfaction and adherence to COPD treatment (SAT) study follow-up. Respir Med. 2019;(153):68-75. doi: 10.1016/j.rmed.2019.05.017..
DOI: 10.1016/j.rmed.2019.05.017
Scalone G., Nava S., Ventrella F., Bussoli G., Catapano G.A., Pennisi A., Dadduzio F., Schino P., Pela R., Bartezaghi M., Morini P., Porpiglia A., Muscianisi E.; Mistral study group. Pharmacological approach and adherence to treatment recommendations in frequently and non-frequently exacerbating COPD patients from Italy: MISTRAL – The prospective cohort, observational study. Pulm Pharmacol Ther. 2018;53:68-77. doi: 10.1016/j.pupt.2018.09.001..
DOI: 10.1016/j.pupt.2018.09.001